New Patents ISSUED
Synthetic Blood International Inc. Announces Issuance of Two New Patents
Business Wire - January 19, 1999 09:18
KETTERING, Ohio--(BUSINESS WIRE)--Jan. 19, 1999--Synthetic Blood International Inc. (SYBD) announced today that two new U.S. patents protecting the company's proprietary perfluorocarbon blood substitute and liquid ventilation technology have been issued.
The patents, titled "Perfluorocarbons for biological gas exchange and method" and "Method of assisting normal breathing in a mammal having a lung disorder," claim the use of new perfluorocarbons with improved biological and gas exchange properties. Also claimed is the novel use of two perfluorocarbons with different vapor pressures to control perfluorocarbon persistence and duration of therapeutic activity.
"We are very pleased to be able to add two important, new patents to SYBD's patent portfolio," said Richard Kiral, Ph.D., vice president of product development. "Our perfluorocarbon and biosensor technology platforms are now protected by more than 20 issued, licensed, and pending patents."
SYBD is developing Oxycyte(TM), a perfluorocarbon blood substitute emulsion; Fluorovent(TM), a perfluorocarbon liquid ventilation product; and an implanted biosensor for continuous monitoring of blood glucose levels in diabetics.
Synthetic Blood International is located in Kettering, Ohio, with West Coast offices based in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's Web site is sybd.com and e-mail address is sybd@siscom.net.
CONTACT: Synthetic Blood International Inc.
Joan Mahan, 800/809-6054 |
